German biotech CatalYm raises €50 million for GDF-15 inhibitor immunotherapyCatalYm has closed a €50 million ($59m) series B financing round to fund clinical studies of its immunotherapy Share XGerman biotech CatalYm raises €50 million for GDF-15 inhibitor immunotherapyhttps://pharmaphorum.com/news/german-biotech-catalym-raises-e50-million-for-gdf-15-inhibitor-immunotherapy/